Jupiter Neurosciences (NASDAQ:JUNS) surge cools as $100 million MDMA agreement strains funding resources
Jupiter Neurosciences shares gave up much of an earlier 67% rally on Tuesday after securing U.S. rights for a trial-stage MDMA drug. The stock was up 6.2% at $0.1752 as of 12:50 p.m. EDT.